[go: up one dir, main page]

EA200300566A1 - Применение cci-779 в качестве противоопухолевого средства - Google Patents

Применение cci-779 в качестве противоопухолевого средства

Info

Publication number
EA200300566A1
EA200300566A1 EA200300566A EA200300566A EA200300566A1 EA 200300566 A1 EA200300566 A1 EA 200300566A1 EA 200300566 A EA200300566 A EA 200300566A EA 200300566 A EA200300566 A EA 200300566A EA 200300566 A1 EA200300566 A1 EA 200300566A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cci
application
tumor
media
tumor media
Prior art date
Application number
EA200300566A
Other languages
English (en)
Other versions
EA007096B1 (ru
Inventor
Гари Дьюкарт
Джеймс Джозеф мл. Гиббонс
Лайза Энн Шпайхер
Филип Фрост
Кэролайн Мэри Дискафани-Марро
Original Assignee
Уайт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Уайт filed Critical Уайт
Publication of EA200300566A1 publication Critical patent/EA200300566A1/ru
Publication of EA007096B1 publication Critical patent/EA007096B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Данное изобретение относится к применению CCI-779 для лечения новообразований.Отчет о международном поиске был опубликован 2002.09.06.
EA200300566A 2000-11-15 2001-11-13 Применение cci-779 в качестве противоопухолевого средства EA007096B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24907700P 2000-11-15 2000-11-15
PCT/US2001/047324 WO2002040000A2 (en) 2000-11-15 2001-11-13 Use of cci-779 as an antineoplastic agent

Publications (2)

Publication Number Publication Date
EA200300566A1 true EA200300566A1 (ru) 2003-10-30
EA007096B1 EA007096B1 (ru) 2006-06-30

Family

ID=22941961

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300566A EA007096B1 (ru) 2000-11-15 2001-11-13 Применение cci-779 в качестве противоопухолевого средства

Country Status (27)

Country Link
US (3) US20020091137A1 (ru)
EP (1) EP1335725B1 (ru)
JP (4) JP4472251B2 (ru)
KR (1) KR100827942B1 (ru)
CN (2) CN102058588A (ru)
AR (1) AR031341A1 (ru)
AT (1) ATE393629T1 (ru)
AU (2) AU2731302A (ru)
BR (1) BR0115323A (ru)
CA (1) CA2429020C (ru)
CY (1) CY1108109T1 (ru)
DE (1) DE60133831T2 (ru)
DK (1) DK1335725T3 (ru)
EA (1) EA007096B1 (ru)
ES (1) ES2305134T3 (ru)
HU (1) HUP0400521A3 (ru)
IL (2) IL155871A0 (ru)
MX (1) MXPA03004192A (ru)
NO (1) NO20032181D0 (ru)
NZ (1) NZ539668A (ru)
PL (1) PL207061B1 (ru)
PT (1) PT1335725E (ru)
SG (1) SG148031A1 (ru)
SI (1) SI1335725T1 (ru)
TW (1) TWI286074B (ru)
WO (1) WO2002040000A2 (ru)
ZA (1) ZA200304603B (ru)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
EP2269603B1 (en) 2001-02-19 2015-05-20 Novartis AG Treatment of breast tumors with a rapamycin derivative in combination with exemestane
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
SG153647A1 (en) * 2001-06-01 2009-07-29 Wyeth Corp Antineoplastic combinations
EP2407473A3 (en) * 2002-02-01 2012-03-21 ARIAD Pharmaceuticals, Inc Method for producing phosphorus-containing compounds
JP2005531391A (ja) * 2002-06-27 2005-10-20 微創医療器械（上海）有限公司 薬剤放出ステント
BR0313024A (pt) 2002-07-30 2005-07-12 Wyeth Corp Formulações parenterais contendo um hidroxiéster de rapamicina
WO2004026280A2 (en) * 2002-09-17 2004-04-01 Wyeth Granulate formulation of the rapamycin ester cci-779
JP2006514554A (ja) 2002-11-21 2006-05-11 ワイス 腎細胞癌および他の固形腫瘍の診断法
US20050287532A9 (en) * 2003-02-11 2005-12-29 Burczynski Michael E Methods for monitoring drug activities in vivo
CA2515677A1 (en) * 2003-02-11 2004-08-26 Wyeth Methods for monitoring drug activities in vivo
US7643943B2 (en) 2003-02-11 2010-01-05 Wyeth Llc Methods for monitoring drug activities in vivo
UA83484C2 (ru) * 2003-03-05 2008-07-25 Уайт Способ лечения рака молочной железы комбинацией производного рапамицина и ингибитора ароматазы - летрозола, фармацевтическая композиция
EP1615640B1 (en) * 2003-04-22 2007-01-24 Wyeth Antineoplastic combinations
EP1618218A2 (en) * 2003-04-29 2006-01-25 Wyeth Methods for prognosis and treatment of solid tumors
KR20060052880A (ko) * 2003-07-25 2006-05-19 와이어쓰 동결건조된 ｃｃｉ- 779 제형
AR046194A1 (es) * 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
EP1701698B1 (en) * 2004-01-08 2008-01-16 Wyeth a Corporation of the State of Delaware Directly compressible pharmaceutical composition for the oral admimistration of cci-779
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
KR101313702B1 (ko) 2005-02-03 2013-10-04 와이어쓰 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
CN101119709A (zh) * 2005-02-15 2008-02-06 惠氏公司 口服生物有效的cci-779配方
TW200803892A (en) * 2005-11-04 2008-01-16 Wyeth Corp Antineoplastic combinations with MTOR inhibitor, herceptin, and/or HKI-272
NO346575B1 (no) * 2005-11-21 2022-10-17 Novartis Ag Anvendelse av 40-O-(2-hydroksyetyl)-rapamycin i behandling av carcinoid eller småøyet celle cancer
KR20080077989A (ko) * 2005-12-20 2008-08-26 와이어쓰 약물의 불순물 조절을 통한 ｃｃｉ-779 제형의 안정성 조절
DE102006011507A1 (de) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US20090076060A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched temsirolimus
US8660003B2 (en) * 2007-10-03 2014-02-25 Genesis Technical Systems Corp. Dynamic, asymmetric rings
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
AU2013205002B2 (en) * 2008-03-21 2016-09-15 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
AU2009225434B2 (en) * 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
DK2310011T3 (da) 2008-06-17 2013-10-14 Wyeth Llc Antineoplastiske kombinationer indeholdende hki-272 og vinorelbin
KR101434009B1 (ko) 2008-08-04 2014-08-25 와이어쓰 엘엘씨 4-아닐리노-3-사이아노퀴놀린과 카페시타빈의 항신생물성 조합물
US9211291B2 (en) 2009-04-06 2015-12-15 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
WO2010132233A1 (en) * 2009-05-13 2010-11-18 The Trustees Of The University Of Pennsylvania Combination antineoplastic therapy
WO2011151704A2 (en) * 2010-06-02 2011-12-08 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of rapamycin esters
US9745941B2 (en) * 2014-04-29 2017-08-29 Ford Global Technologies, Llc Tunable starter resistor
CA2992629C (en) * 2015-08-24 2020-06-30 Shanxi Yabao Health Products Co., Ltd. Use of dihydroxyacetone in preparation of anti-cancer medicaments
CN111110676A (zh) * 2020-03-07 2020-05-08 天津医科大学总医院 阿帕替尼及联合cci-779在制备肺癌药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4885171A (en) 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US4401653A (en) 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5078999A (en) 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5321009A (en) 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
EP0525960B1 (en) 1991-06-18 1996-03-20 American Home Products Corporation Use of rapamycin for the treatment of adult T-cell leukemia/lymphoma
IL102414A (en) 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
US5286731A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5286730A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5516781A (en) 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5288711A (en) 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
MXPA03001245A (es) 2000-08-11 2003-05-27 Wyeth Corp Metodo para el tratamiento del carcionma positivo para receptores de estrogeno.
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI233359B (en) 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569

Also Published As

Publication number Publication date
CN102058588A (zh) 2011-05-18
IL155871A0 (en) 2003-12-23
US20030153593A1 (en) 2003-08-14
TWI286074B (en) 2007-09-01
EA007096B1 (ru) 2006-06-30
AU2007201324B2 (en) 2010-11-18
DE60133831D1 (de) 2008-06-12
NO20032181L (no) 2003-05-14
HUP0400521A2 (hu) 2004-06-28
WO2002040000A2 (en) 2002-05-23
US7781446B2 (en) 2010-08-24
DE60133831T2 (de) 2009-05-20
SG148031A1 (en) 2008-12-31
AU2007201324A1 (en) 2007-04-19
IL155871A (en) 2012-03-29
JP2004517065A (ja) 2004-06-10
KR100827942B1 (ko) 2008-05-13
ZA200304603B (en) 2004-09-13
US20020091137A1 (en) 2002-07-11
NZ539668A (en) 2007-06-29
WO2002040000A3 (en) 2002-09-06
MXPA03004192A (es) 2003-09-22
CA2429020A1 (en) 2002-05-23
US20070142425A1 (en) 2007-06-21
JP2014088430A (ja) 2014-05-15
NO20032181D0 (no) 2003-05-14
HK1058008A1 (en) 2004-04-30
CN1678312A (zh) 2005-10-05
SI1335725T1 (sl) 2008-08-31
ES2305134T3 (es) 2008-11-01
CY1108109T1 (el) 2014-02-12
CA2429020C (en) 2009-05-26
PT1335725E (pt) 2008-06-19
AU2731302A (en) 2002-05-27
PL207061B1 (pl) 2010-10-29
US7189735B2 (en) 2007-03-13
JP2010018620A (ja) 2010-01-28
DK1335725T3 (da) 2008-06-30
KR20040029309A (ko) 2004-04-06
ATE393629T1 (de) 2008-05-15
PL362740A1 (en) 2004-11-02
JP4472251B2 (ja) 2010-06-02
EP1335725A2 (en) 2003-08-20
EP1335725B1 (en) 2008-04-30
BR0115323A (pt) 2004-02-17
AR031341A1 (es) 2003-09-17
JP2016094444A (ja) 2016-05-26
HUP0400521A3 (en) 2007-05-29

Similar Documents

Publication Publication Date Title
EA200300566A1 (ru) Применение cci-779 в качестве противоопухолевого средства
EA200400006A1 (ru) Бензоилсульфонамиды и сульфонилбензамидины для применения в качестве противоопухолевых агентов
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE60230890D1 (de) Indolizine als kinaseproteinhemmer
SE0000540D0 (sv) New compounds
DE60108754D1 (de) Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum
PT695758E (pt) Amidas e esteres de pentapeptidos inibidores de cancro humano
EA200501251A1 (ru) Антинеопластические комбинации
DK1259512T3 (da) Pteridinforbindelser til behandling af psoreasis
DE60135919D1 (de) Farnesyl transferase-hemmende 6-heterocyclylmethyl-chinolin und chinazol-derivate
DE69919700D1 (de) Überbrückte indenopyrrolocarbazole
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
PT1473036E (pt) Solvato de hemitartarato de zolpidem
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
SE9901077D0 (sv) Novel use
DK1313740T3 (da) Prodrugs af imidazopyridinderivater
SE9801494D0 (sv) Novel use
BR9807883A (pt) Compostos de tetraidropirido
SE0003476D0 (sv) Compounds
DE60127131D1 (de) Tricyclische imidazopyridine
BRPI0408117A (pt) compostos heterocìclicos bifuncionais e métodos de produção e uso dos mesmos
DK1073447T3 (da) N1-modificerede glycopeptider
EA200200798A1 (ru) Кальцилитические соединения
EA200500878A1 (ru) Кальцилитические соединения
ID27656A (id) Turunan azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MK4A Patent expired

Designated state(s): RU